{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:57:39Z","timestamp":1793642259652,"version":"4.5.1"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2019,4,12]],"date-time":"2019-04-12T00:00:00Z","timestamp":1555027200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100004484","name":"Tehran University of Medical Sciences and Health Services","doi-asserted-by":"publisher","award":["32601"],"award-info":[{"award-number":["32601"]}],"id":[{"id":"10.13039\/501100004484","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Child Adolesc Psychiatry"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s00787-019-01333-5","type":"journal-article","created":{"date-parts":[[2019,4,12]],"date-time":"2019-04-12T07:03:06Z","timestamp":1555052586000},"page":"1619-1628","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Baclofen as an adjuvant therapy for autism: a randomized, double-blind, placebo-controlled trial"],"prefix":"10.1007","volume":"28","author":[{"given":"Seyedeh-Mahsa","family":"Mahdavinasab","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amene","family":"Saghazadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nogol","family":"Motamed-Gorji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salar","family":"Vaseghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad-Reza","family":"Mohammadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Alichani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2277-5101","authenticated-orcid":false,"given":"Shahin","family":"Akhondzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,4,12]]},"reference":[{"key":"1333_CR1","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and statistical manual of mental disorders (DSM-5\u00ae)","author":"A American Psychiatric","year":"2013","unstructured":"American Psychiatric A (2013) Diagnostic and statistical manual of mental disorders (DSM-5\u00ae). American Psychiatric Publishing, Wachington, DC"},{"issue":"1","key":"1333_CR2","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1001\/archgenpsychiatry.2009.137","volume":"67","author":"K Nakamura","year":"2010","unstructured":"Nakamura K, Sekine Y, Ouchi Y, Tsujii M, Yoshikawa E, Futatsubashi M et al (2010) Brain serotonin and dopamine transporter bindings in adults with high-functioning autism. Arch Gene Pychiatry 67(1):59\u201368","journal-title":"Arch Gene Pychiatry"},{"issue":"5","key":"1333_CR3","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2165\/00023210-200620050-00004","volume":"20","author":"J Horacek","year":"2006","unstructured":"Horacek J, Bubenikova-Valesova V, Kopecek M, Palenicek T, Dockery C, Mohr P et al (2006) Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Dugs 20(5):389\u2013409","journal-title":"CNS Dugs"},{"issue":"3","key":"1333_CR4","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.eurpsy.2010.09.011","volume":"26","author":"M Hert De","year":"2011","unstructured":"De Hert M, Dobbelaere M, Sheridan EM, Cohen D, Correll CU (2011) Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: a systematic review of randomized, placebo controlled trials and guidelines for clinical practice. Eur Psychiatry 26(3):144\u2013158","journal-title":"Eur Psychiatry"},{"issue":"7","key":"1333_CR5","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1176\/appi.ajp.162.7.1361","volume":"62","author":"Research Units on Pediatric Psychopharmacology Autism N","year":"2005","unstructured":"Research Units on Pediatric Psychopharmacology Autism N (2005) Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6 months. Am J Psychiatry 62(7):1361\u20131369","journal-title":"Am J Psychiatry"},{"issue":"8","key":"1333_CR6","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1212\/WNL.0b013e318247cd03","volume":"78","author":"EE Benarroch","year":"2012","unstructured":"Benarroch EE (2012) GABAB receptors: structure, functions, and clinical implications. Neurology 78(8):578\u2013584","journal-title":"Neurology"},{"issue":"1","key":"1333_CR7","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.tips.2004.11.004","volume":"26","author":"JF Cryan","year":"2005","unstructured":"Cryan JF, Kaupmann K (2005) Don\u2019t worry \u2018B\u2019happy!: a role for GABAB receptors in anxiety and depression. Trends Pharmacol Sci 26(1):36\u201343","journal-title":"Trends Pharmacol Sci"},{"issue":"2","key":"1333_CR8","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s10803-008-0646-7","volume":"39","author":"SH Fatemi","year":"2009","unstructured":"Fatemi SH, Reutiman TJ, Folsom TD, Thuras PD (2009) GABA A receptor downregulation in brains of subjects with autism. J Autism Dev Disord 39(2):223","journal-title":"J Autism Dev Disord"},{"issue":"1","key":"1333_CR9","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s12311-008-0075-3","volume":"8","author":"SH Fatemi","year":"2009","unstructured":"Fatemi SH, Folsom TD, Reutiman TJ, Thuras PD (2009) Expression of GABA B receptors is altered in brains of subjects with autism. Cerebellum 8(1):64\u201369","journal-title":"Cerebellum"},{"issue":"6","key":"1333_CR10","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1023\/A:1013238809666","volume":"31","author":"GJ Blatt","year":"2001","unstructured":"Blatt GJ, Fitzgerald CM, Guptill JT, Booker AB, Kemper TL, Bauman ML (2001) Density and distribution of hippocampal neurotransmitter receptors in autism: an autoradiographic study. J Autism Dev Disord 31(6):537\u2013543","journal-title":"J Autism Dev Disord"},{"issue":"4","key":"1333_CR11","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1093\/hmg\/ddi045","volume":"14","author":"RC Samaco","year":"2005","unstructured":"Samaco RC, Hogart A, LaSalle JM (2005) Epigenetic overlap in autism-spectrum neurodevelopmental disorders: MECP2 deficiency causes reduced expression of UBE3A and GABRB3. Hum Mol Gen 14(4):483\u2013492","journal-title":"Hum Mol Gen"},{"issue":"5","key":"1333_CR12","first-page":"1414","volume":"114","author":"AL Oblak","year":"2010","unstructured":"Oblak AL, Gibbs TT, Blatt GJ (2010) Decreased GABA(B) receptors in the cingulate cortex and fusiform gyrus in autism. J Neurochem 114(5):1414\u20131423","journal-title":"J Neurochem"},{"key":"1333_CR13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neuroimage.2013.05.068","volume":"86","author":"W Gaetz","year":"2014","unstructured":"Gaetz W, Bloy L, Wang DJ, Port RG, Blaskey L, Levy SE et al (2014) GABA estimation in the brains of children on the autism spectrum: measurement precision and regional cortical variation. Neuroimage 86:1\u20139","journal-title":"Neuroimage"},{"issue":"8","key":"1333_CR14","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.braindev.2011.10.007","volume":"34","author":"T Mori","year":"2012","unstructured":"Mori T, Mori K, Fujii E, Toda Y, Miyazaki M, Harada M et al (2012) Evaluation of the GABAergic nervous system in autistic brain: (123)I-iomazenil SPECT study. Brain Dev 34(8):648\u2013654","journal-title":"Brain Dev"},{"issue":"1","key":"1333_CR15","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/aur.62","volume":"2","author":"J Yip","year":"2009","unstructured":"Yip J, Soghomonian Jean J, Blatt Gene J (2009) Decreased GAD65 mRNA levels in select subpopulations of neurons in the cerebellar dentate nuclei in autism: an in situ hybridization study. Autism Res 2(1):50\u201359","journal-title":"Autism Res"},{"issue":"10","key":"1333_CR16","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1002\/ar.21252","volume":"294","author":"GJ Blatt","year":"2011","unstructured":"Blatt GJ, Fatemi SH (2011) Alterations in GABAergic biomarkers in the autism brain: research findings and clinical implications. Anatomical Rec 294(10):1646\u20131652","journal-title":"Anatomical Rec"},{"issue":"8","key":"1333_CR17","first-page":"PR1","volume":"8","author":"D Dhossche","year":"2002","unstructured":"Dhossche D, Applegate H, Abraham A, Maertens P, Bland L, Bencsath A et al (2002) Elevated plasma gamma-aminobutyric acid (GABA) levels in autistic youngsters: stimulus for a GABA hypothesis of autism. Med Sci Monitor 8(8):PR1\u2013PR6","journal-title":"Med Sci Monitor"},{"issue":"9","key":"1333_CR18","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1038\/npp.2015.66","volume":"40","author":"JL Silverman","year":"2015","unstructured":"Silverman JL, Pride MC, Hayes JE, Puhger KR, Butler-Struben HM, Baker S et al (2015) GABA B receptor agonist R-baclofen reverses social deficits and reduces repetitive behavior in Two mouse models of autism. Neuropsychopharmacol 40(9):2228","journal-title":"Neuropsychopharmacol"},{"issue":"3","key":"1333_CR19","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/npp.2017.236","volume":"43","author":"LJ Stoppel","year":"2018","unstructured":"Stoppel LJ, Kazdoba TM, Schaffler MD, Preza AR, Heynen A, Crawley JN et al (2018) R-baclofen reverses cognitive deficits and improves social interactions in two lines of 16p11. 2 deletion mice. Neuropsychopharmacol 43(3):513","journal-title":"Neuropsychopharmacol"},{"issue":"4","key":"1333_CR20","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1007\/s10803-013-1963-z","volume":"44","author":"CA Erickson","year":"2014","unstructured":"Erickson CA, Veenstra-Vanderweele JM, Melmed RD, McCracken JT, Ginsberg LD, Sikich L et al (2014) STX209 (arbaclofen) for autism spectrum disorders: an 8-week open-label study. J Autism Dev Disord 44(4):958\u2013964","journal-title":"J Autism Dev Disord"},{"issue":"7","key":"1333_CR21","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1038\/npp.2016.237","volume":"42","author":"J Veenstra-VanderWeele","year":"2017","unstructured":"Veenstra-VanderWeele J, Cook EH, King BH, Zarevics P, Cherubini M, Walton-Bowen K et al (2017) Arbaclofen in children and adolescents with autism spectrum disorder: a randomized, controlled, phase 2 trial. Neuropsychopharmacol 42(7):1390\u20131398","journal-title":"Neuropsychopharmacol"},{"issue":"3","key":"1333_CR22","first-page":"14","volume":"81","author":"General Assembly of the World Medical Association","year":"2014","unstructured":"General Assembly of the World Medical Association (2014) World medical association declaration of Helsinki: ethical principles for medical research involving human subjects. J Am Coll Dent 81(3):14","journal-title":"J Am Coll Dent"},{"key":"1333_CR23","unstructured":"Association AP. Diagnostic and statistical manual of mental disorders (DSM-5\u00ae). American Psychiatric Pub; 2013"},{"issue":"3","key":"1333_CR24","first-page":"283","volume":"100","author":"MG Aman","year":"1995","unstructured":"Aman MG, Burrow WH, Wolford PL (1995) The Aberrant Behavior Checklist-Community: factor validity and effect of subject variables for adults in group homes. Am J Mental Retard 100(3):283\u2013292","journal-title":"Am J Mental Retard"},{"issue":"5","key":"1333_CR25","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/BF02172145","volume":"24","author":"C Lord","year":"1994","unstructured":"Lord C, Rutter M, Le Couteur A (1994) Autism Diagnostic Interview-Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. J Autism Dev Disord 24(5):659\u2013685","journal-title":"J Autism Dev Disord"},{"issue":"5","key":"1333_CR26","first-page":"485","volume":"89","author":"MG Aman","year":"1985","unstructured":"Aman MG, Singh NN, Stewart AW, Field CJ (1985) The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects. Am J Ment Defic 89(5):485\u2013491","journal-title":"Am J Ment Defic"},{"issue":"3","key":"1333_CR27","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s10048-006-0045-1","volume":"7","author":"AL Collins","year":"2006","unstructured":"Collins AL, Ma D, Whitehead PL, Martin ER, Wright HH, Abramson RK et al (2006) Investigation of autism and GABA receptor subunit genes in multiple ethnic groups. Neurogenetics 7(3):167\u2013174","journal-title":"Neurogenetics"},{"issue":"1","key":"1333_CR28","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/(SICI)1096-8628(20000207)96:1<43::AID-AJMG9>3.0.CO;2-3","volume":"96","author":"ER Martin","year":"2000","unstructured":"Martin ER, Menold MM, Wolpert CM, Bass MP, Donnelly SL, Ravan SA et al (2000) Analysis of linkage disequilibrium in gamma-aminobutyric acid receptor subunit genes in autistic disorder. Am J Med Gen 96(1):43\u201348","journal-title":"Am J Med Gen"},{"issue":"1","key":"1333_CR29","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/ajmg.b.30038","volume":"131","author":"JL McCauley","year":"2004","unstructured":"McCauley JL, Olson LM, Delahanty R, Amin T, Nurmi EL, Organ EL et al (2004) A linkage disequilibrium map of the 1-Mb 15q12 GABA(A) receptor subunit cluster and association to autism. Am J Med Genetics B Neuropsychiatric Gen 131(1):51\u201359","journal-title":"Am J Med Genetics B Neuropsychiatric Gen"},{"issue":"3","key":"1333_CR30","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1086\/433195","volume":"77","author":"DQ Ma","year":"2005","unstructured":"Ma DQ, Whitehead PL, Menold MM, Martin ER, Ashley-Koch AE, Mei H et al (2005) Identification of significant association and gene-gene interaction of GABA receptor subunit genes in autism. Am J Hum Gen 77(3):377\u2013388","journal-title":"Am J Hum Gen"},{"issue":"3","key":"1333_CR31","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s10048-006-0045-1","volume":"7","author":"AL Collins","year":"2006","unstructured":"Collins AL, Ma D, Whitehead PL, Martin ER, Wright HH, Abramson RK et al (2006) Investigation of autism and GABA receptor subunit genes in multiple ethnic groups. Neurogenetics 7(3):167\u2013174","journal-title":"Neurogenetics"},{"issue":"3","key":"1333_CR32","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1159\/000098651","volume":"54","author":"SA Kim","year":"2006","unstructured":"Kim SA, Kim JH, Park M, Cho IH, Yoo HJ (2006) Association of GABRB3 polymorphisms with autism spectrum disorders in Korean trios. Neuropsychobiology 54(3):160\u2013165","journal-title":"Neuropsychobiology"},{"issue":"6","key":"1333_CR33","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1093\/hmg\/ddm014","volume":"16","author":"A Hogart","year":"2007","unstructured":"Hogart A, Nagarajan RP, Patzel KA, Yasui DH, Lasalle JM (2007) 15q11-13 GABAA receptor genes are normally biallelically expressed in brain yet are subject to epigenetic dysregulation in autism-spectrum disorders. Hum Mol Gen 16(6):691\u2013703","journal-title":"Hum Mol Gen"},{"issue":"5806","key":"1333_CR34","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1126\/science.1133212","volume":"314","author":"R Tyzio","year":"2006","unstructured":"Tyzio R, Cossart R, Khalilov I, Minlebaev M, H\u00fcbner CA, Represa A et al (2006) Maternal oxytocin triggers a transient inhibitory switch in GABA signaling in the fetal brain during delivery. Science 314(5806):1788\u20131792","journal-title":"Science"},{"issue":"6171","key":"1333_CR35","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1126\/science.1247190","volume":"343","author":"R Tyzio","year":"2014","unstructured":"Tyzio R, Nardou R, Ferrari DC, Tsintsadze T, Shahrokhi A, Eftekhari S et al (2014) Oxytocin-mediated GABA inhibition during delivery attenuates autism pathogenesis in rodent offspring. Science 343(6171):675","journal-title":"Science"},{"issue":"3","key":"1333_CR36","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1093\/cercor\/bhq124","volume":"21","author":"DD Wang","year":"2011","unstructured":"Wang DD, Kriegstein AR (2011) Blocking Early GABA depolarization with bumetanide results in permanent alterations in cortical circuits and sensorimotor gating deficits. Cereb Cortex 21(3):574\u2013587","journal-title":"Cereb Cortex"},{"issue":"7","key":"1333_CR37","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.biopsych.2009.09.020","volume":"67","author":"AJ Guastella","year":"2010","unstructured":"Guastella AJ, Einfeld SL, Gray KM, Rinehart NJ, Tonge BJ, Lambert TJ et al (2010) Intranasal oxytocin improves emotion recognition for youth with autism spectrum disorders. Biol Psychiatry 67(7):692\u2013694","journal-title":"Biol Psychiatry"},{"issue":"4","key":"1333_CR38","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.biopsych.2006.05.030","volume":"61","author":"E Hollander","year":"2007","unstructured":"Hollander E, Bartz J, Chaplin W, Phillips A, Sumner J, Soorya L et al (2007) Oxytocin increases retention of social cognition in autism. Biol Psychiatry 61(4):498\u2013503","journal-title":"Biol Psychiatry"},{"issue":"1","key":"1333_CR39","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/sj.npp.1300021","volume":"28","author":"E Hollander","year":"2003","unstructured":"Hollander E, Novotny S, Hanratty M, Yaffe R, DeCaria CM, Aronowitz BR et al (2003) Oxytocin infusion reduces repetitive behaviors in adults with autistic and Asperger\u2019s disorders. Neuropsychopharmaco 28(1):193","journal-title":"Neuropsychopharmaco"},{"issue":"6","key":"1333_CR40","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s10803-009-0924-z","volume":"40","author":"SH Fatemi","year":"2010","unstructured":"Fatemi SH, Reutiman TJ, Folsom TD, Rooney RJ, Patel DH, Thuras PD (2010) mRNA and protein levels for GABA A \u03b14, \u03b15, \u03b21 and GABA B R1 receptors are altered in brains from subjects with autism. J Autism Develop Disord 40(6):743\u2013750","journal-title":"J Autism Develop Disord"},{"issue":"3","key":"1333_CR41","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1080\/14734220500208846","volume":"4","author":"JA Laurence","year":"2005","unstructured":"Laurence JA, Fatemi SH (2005) Glial fibrillary acidic protein is elevated in superior frontal, parietal and cerebellar cortices of autistic subjects. Cerebellum 4(3):206\u2013210","journal-title":"Cerebellum"},{"issue":"2","key":"1333_CR42","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.bbr.2007.09.009","volume":"187","author":"TM DeLorey","year":"2008","unstructured":"DeLorey TM, Sahbaie P, Hashemi E, Homanics GE, Clark JD (2008) Gabrb3 gene deficient mice exhibit impaired social and exploratory behaviors, deficits in non-selective attention and hypoplasia of cerebellar vermal lobules: a potential model of autism spectrum disorder. Behav Brain Res 187(2):207\u2013220","journal-title":"Behav Brain Res"},{"issue":"1","key":"1333_CR43","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.bbr.2010.06.032","volume":"216","author":"TM DeLorey","year":"2011","unstructured":"DeLorey TM, Sahbaie P, Hashemi E, Li WW, Salehi A, Clark DJ (2011) Somatosensory and sensorimotor consequences associated with the heterozygous disruption of the autism candidate gene, Gabrb3. Behav Brain Res 216(1):36\u201345","journal-title":"Behav Brain Res"},{"issue":"9","key":"1333_CR44","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.biopsych.2010.12.022","volume":"69","author":"M Sala","year":"2011","unstructured":"Sala M, Braida D, Lentini D, Busnelli M, Bulgheroni E, Capurro V et al (2011) Pharmacologic rescue of impaired cognitive flexibility, social deficits, increased aggression, and seizure susceptibility in oxytocin receptor null mice: a neurobehavioral model of autism. Biol Psychiatry 69(9):875\u2013882","journal-title":"Biol Psychiatry"},{"issue":"6","key":"1333_CR45","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1017\/S1461145712001216","volume":"16","author":"A Banerjee","year":"2013","unstructured":"Banerjee A, Garcia-Oscos F, Roychowdhury S, Galindo LC, Hall S, Kilgard MP (2013) Impairment of cortical GABAergic synaptic transmission in an environmental rat model of autism. Int J Neuropsychopharmacol 16(6):1309\u20131318","journal-title":"Int J Neuropsychopharmacol"},{"issue":"5","key":"1333_CR46","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1017\/neu.2016.59","volume":"29","author":"F Bertelsen","year":"2017","unstructured":"Bertelsen F, Moller A, Folloni D, Drasbek KR, Scheel-Kruger J, Landau AM (2017) Increased GABAA receptor binding in amygdala after prenatal administration of valproic acid to rats. Acta Neuropsychiatr 29(5):309\u2013314","journal-title":"Acta Neuropsychiatr"},{"issue":"6","key":"1333_CR47","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.neuron.2014.01.016","volume":"81","author":"S Han","year":"2014","unstructured":"Han S, Tai C, Jones CJ, Scheuer T, Catterall WA (2014) Enhancement of inhibitory neurotransmission by GABAA receptors having alpha2,3-subunits ameliorates behavioral deficits in a mouse model of autism. Neuron 81(6):1282\u20131289","journal-title":"Neuron"},{"key":"1333_CR48","doi-asserted-by":"crossref","first-page":"10861","DOI":"10.1038\/ncomms10861","volume":"7","author":"T Nakamura","year":"2016","unstructured":"Nakamura T, Arima-Yoshida F, Sakaue F, Nasu-Nishimura Y, Takeda Y, Matsuura K et al (2016) PX-RICS-deficient mice mimic autism spectrum disorder in Jacobsen syndrome through impaired GABAA receptor trafficking. Nat Commun 7:10861","journal-title":"Nat Commun"},{"issue":"1","key":"1333_CR49","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0306-9877(02)00157-3","volume":"59","author":"BI Cohen","year":"2002","unstructured":"Cohen BI (2002) Use of a GABA-transaminase agonist for treatment of infantile autism. Med Hypotheses 59(1):115\u2013116","journal-title":"Med Hypotheses"},{"key":"1333_CR50","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.neuropharm.2015.11.003","volume":"102","author":"N Kratsman","year":"2016","unstructured":"Kratsman N, Getselter D, Elliott E (2016) Sodium butyrate attenuates social behavior deficits and modifies the transcription of inhibitory\/excitatory genes in the frontal cortex of an autism model. Neuropharmacol 102:136\u2013145","journal-title":"Neuropharmacol"},{"issue":"5","key":"1333_CR51","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1159\/000332884","volume":"33","author":"JL Olmos-Serrano","year":"2011","unstructured":"Olmos-Serrano JL, Corbin JG, Burns MP (2011) The GABA(A) receptor agonist THIP ameliorates specific behavioral deficits in the mouse model of fragile X syndrome. Dev Neurosci 33(5):395\u2013403","journal-title":"Dev Neurosci"},{"issue":"23","key":"1333_CR52","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1056\/NEJM198906083202303","volume":"320","author":"RD Penn","year":"1989","unstructured":"Penn RD, Savoy SM, Corcos D, Latash M, Gottlieb G, Parke B et al (1989) Intrathecal baclofen for severe spinal spasticity. New Engl J Med 320(23):1517\u20131521","journal-title":"New Engl J Med"},{"issue":"4","key":"1333_CR53","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.jpeds.2006.05.029","volume":"149","author":"TI Omari","year":"2006","unstructured":"Omari TI, Benninga MA, Sansom L, Butler RN, Dent J, Davidson GP (2006) Effect of baclofen on esophagogastric motility and gastroesophageal reflux in children with gastroesophageal reflux disease: a randomized controlled trial. J Pediatrics 149(4):468\u2013474","journal-title":"J Pediatrics"},{"issue":"11","key":"1333_CR54","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1111\/j.1530-0277.2010.01273.x","volume":"34","author":"JC Garbutt","year":"2010","unstructured":"Garbutt JC, Kampov-Polevoy AB, Gallop R, Kalka-Juhl L, Flannery BA (2010) Efficacy and safety of baclofen for alcohol dependence: a randomized, double-blind, placebo-controlled trial. Alcoholism Clin Exp Res 34(11):1849\u20131857","journal-title":"Alcoholism Clin Exp Res"},{"issue":"3","key":"1333_CR55","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1124\/jpet.108.149773","volume":"330","author":"R Lal","year":"2009","unstructured":"Lal R, Sukbuntherng J, Tai EH, Upadhyay S, Yao F, Warren MS et al (2009) Arbaclofen placarbil, a novel R-baclofen prodrug: improved absorption, distribution, metabolism, and elimination properties compared with R-baclofen. J Pharmacol Exp Therapeutics 330(3):911\u2013921","journal-title":"J Pharmacol Exp Therapeutics"},{"issue":"152","key":"1333_CR56","doi-asserted-by":"crossref","first-page":"152ra28","DOI":"10.1126\/scitranslmed.3004218","volume":"4","author":"C Henderson","year":"2012","unstructured":"Henderson C, Wijetunge L, Kinoshita MN, Shumway M, Hammond RS, Postma FR et al (2012) Reversal of disease-related pathologies in the fragile X mouse model by selective activation of GABAB receptors with arbaclofen. Sci Translational Med 4(152):152ra28","journal-title":"Sci Translational Med"},{"key":"1333_CR57","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyv034","author":"M Qin","year":"2015","unstructured":"Qin M, Huang T, Kader M, Krych L, Xia Z, Burlin T, Zeidler Z, Zhao T, Smith CB (2015) R-Baclofen reverses a social behavior deficit and elevated protein synthesis in a mouse model of fragile X syndrome. Int J Neuropsychopharmacol. \nhttps:\/\/doi.org\/10.1093\/ijnp\/pyv034","journal-title":"Int J Neuropsychopharmacol"},{"key":"1333_CR58","doi-asserted-by":"publisher","DOI":"10.1523\/ENEURO.0380-16.2017","author":"D Sinclair","year":"2017","unstructured":"Sinclair D, Featherstone R, Naschek M, Nam J, Du A, Wright S, Pance K, Melnychenko O, Weger R, Akuzawa S, Matsumoto M, Siegel SJ (2017) GABA-B Agonist baclofen normalizes auditory-evoked neural oscillations and behavioral deficits in the Fmr1 knockout mouse model of Fragile X syndrome. eNeuro. \nhttps:\/\/doi.org\/10.1523\/ENEURO.0380-16.2017","journal-title":"eNeuro"},{"key":"1333_CR59","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s11689-016-9181-6","volume":"9","author":"E Berry-Kravis","year":"2017","unstructured":"Berry-Kravis E, Hagerman R, Visootsak J, Budimirovic D, Kaufmann WE, Cherubini M et al (2017) Arbaclofen in fragile X syndrome: results of phase 3 trials. J Neurodevelop Disord 9:3","journal-title":"J Neurodevelop Disord"},{"issue":"9","key":"1333_CR60","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1038\/npp.2015.66","volume":"40","author":"JL Silverman","year":"2015","unstructured":"Silverman JL, Pride MC, Hayes JE, Puhger KR, Butler-Struben HM, Baker S et al (2015) GABAB receptor agonist R-baclofen reverses social deficits and reduces repetitive behavior in two mouse models of autism. Neuropsychopharmacol 40(9):2228\u20132239","journal-title":"Neuropsychopharmacol"},{"key":"1333_CR61","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.nbd.2017.08.013","volume":"108","author":"RG Port","year":"2017","unstructured":"Port RG, Gajewski C, Krizman E, Dow HC, Hirano S, Brodkin ES et al (2017) Protocadherin 10 alters gamma oscillations, amino acid levels, and their coupling; baclofen partially restores these oscillatory deficits. Neurobiol Dis 108:324\u2013338","journal-title":"Neurobiol Dis"}],"container-title":["European Child &amp; Adolescent Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00787-019-01333-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00787-019-01333-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00787-019-01333-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,10]],"date-time":"2020-04-10T23:06:48Z","timestamp":1586560008000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00787-019-01333-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,12]]},"references-count":61,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1333"],"URL":"https:\/\/doi.org\/10.1007\/s00787-019-01333-5","relation":{},"ISSN":["1018-8827","1435-165X"],"issn-type":[{"value":"1018-8827","type":"print"},{"value":"1435-165X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,12]]},"assertion":[{"value":"26 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}